Early Intervention Combined with Targeted Treatment Promotes Cognitive and Behavioral Improvements in Young Children with Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability due to an expansion in the full mutation range (>200 CGG repeats) of the promoter region of the FMR1 gene leading to gene silencing. Lack of FMRP, a critical protein for dendritic spine formation and maturation, will cause FXS. Early environmental enrichment combined with pharmacological intervention has been proven to rescue dendritic spine abnormalities in the animal model of FXS. Here we report on 2 young children with FXS who were treated early with a combination of targeted treatment and intensive educational interventions leading to improvement in their cognition and behavior and a normal IQ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“The absence of FMRP causes impairment of synaptic plasticity [6] that includes upregulation of various proteins including matrix metalloproteinase 9 (MMP9) [7], upregulation of the metabotropic glutamate receptor 5 (mGluR5) pathway [8], and downregulation of the gammaaminobutyric acid (GABA) receptors [9, 10].”
BackgroundFragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051 · cited 1×
“acids (mRNAs) to the synapse, where it regulates protein synthesis usually through suppression of translation [1, 2].”
BackgroundAdult brain neurogenesis and psychiatry: a novel theory of depression
Jacobs, B. L., van Praag, H., & Gage, F. H. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000712 · Cited by 964
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676 · cited 1×
“The absence of FMRP causes impairment of synaptic plasticity [6] that includes upregulation of various proteins including matrix metalloproteinase 9 (MMP9) [7], upregulation of the metabotropic glutamate receptor 5 (mGluR5) pathway [8], and downregulation of the gammaaminobutyric acid (GABA) receptors [9, 10].”
BackgroundDendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome
Irwin, S. A. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.1038 · Cited by 626
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 1×
“The development of targeted treatments for FXS has led to trials of minocycline [11, 12], Arbaclofen [13] and mGluR5 antagonists [14, 15] in patients with FXS.”
BackgroundSelf-citationAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596 · cited 2×
“There are the behavioral and developmental problems in childhood and a variety of medications have been helpful for treating anxiety, aggression, attention deficit hyperactivity disorders (ADHDs), and mood instability [5].”
BackgroundSelf-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 3×
“Minocycline leads to dendritic spine maturation both in culture and in vivo FMR1 knock-out (KO) mice and improves behavior and cognition [7].”
BackgroundA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 1×
“The development of targeted treatments for FXS has led to trials of minocycline [11, 12], Arbaclofen [13] and mGluR5 antagonists [14, 15] in patients with FXS.”
BackgroundSelf-citationRestivo, L., Ferrari, F., Passino, E., Sgobio, C., Bock, J., Oostra, B. A., Bagni, C., & Ammassari-Teule, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504984102 · Cited by 299 · cited 1×
“In another study of the fmr1 KO mouse an enriched environment rescued the abnormalities of the dendritic spines [36].”
Background
Cited by
FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States
Tassone, F., Iong, K. P., Tong, T.-H., Lo, J., Gane, L. W., Berry-Kravis, E., Nguyen, D., Mu, L. Y., Laffin, J., Bailey, D. B., et al. (2012) · Genome Medicine · doi:10.1186/gm401 · Cited by 315
Self-citationFragile X–associated tremor/ataxia syndrome
Hagerman, P. J., & Hagerman, R. J. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12693 · Cited by 172
Self-citationLong-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., Razak, K. A., Ethell, D. W., & Ethell, I. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.058 · Cited by 95
A randomized controlled trial of sertraline in young children with autism spectrum disorder
Potter, L. A., Scholze, D. A., Biag, H. M. B., Schneider, A., Chen, Y., Nguyen, D. V., Rajaratnam, A., Rivera, S. M., Dwyer, P. S., Tassone, F., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00810 · Cited by 43
“These doses were based on those used in previous studies in young children with FXS (27, 29).”
BackgroundMethodSelf-citationAstrocytes in fragile X syndrome
Talvio, K., & Castrén, M. L. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1322541 · Cited by 8
Metadata
- Authors
- Winarni, T. I., Schneider, A., Borodyanskara, M., & Hagerman, R. J.
- Venue
- Case Reports in Genetics
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-4
- ISSN
- 2090-6544 (ISSN-L)
- 2090-6552
- OpenAlex
- W2028980930
- Cited by
- 55
- References
- 15
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.